Astellas Pharma
Last updated Jun 28, 2026
Evidence Sources
3
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
78%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- NSCLC
- AML
Highest priority development: Opportunities for patients and the public to be involved in the work of the MHRA
Regulatory precedent
Why this matters: sets a safety guidance precedent in the same sub-indication (lung cancer) as Astellas Pharma.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 78%
Active Signals
2
Investigate Priority
0
Opportunity Score
40
Buyer Quality
7 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 28, 2026Score 20Gilteritinib Study Launch for ALK-positive NSCLC Patients by Astellas Pharma
Oncology · NSCLC
- MonitorJun 24, 2026Score 20Gilteritinib vs Midostaurin Trial for FLT3 Mutated Acute Myeloid Leukemia
Oncology · AML
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- Opportunities for patients and the public to be involved in the work of the MHRAModerate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)MHRAMHRARegunera - FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)Moderate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Submitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of DrugModerate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Quantitative Systems Pharmacology (QSP)-Based Dose Selection for Minimum Anticipated Biological Effect Level (MABEL) in First-in-Human (FIH) TrialsModerate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Astellas Pharma right now?
- Which regulatory precedents should Astellas Pharma monitor in Oncology and NSCLC?
- Which pipeline programs should Astellas Pharma prioritize for competitive review?
- What signals require immediate investigation for Astellas Pharma?
- Summarize the strategic implications of recent developments for Astellas Pharma.
- Where is the greatest uncertainty in Astellas Pharma's competitive positioning?